Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pen and paper: a new weapon against blood cancer stress?

NCT ID NCT07413991

Symptom relief Sponsor: Blood Cancer United Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study explores whether an online expressive writing workshop can boost mental wellness in young adults (ages 18-39) with blood cancer. One hundred participants will either start the workshop right away or wait four weeks. Everyone takes surveys about their mood and stress over 12 weeks. The goal is to see if writing about emotions can make a real difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Expressive Writing Workshop
What this could lead to
If it works, this could offer a simple, low-cost way to help young adults with blood cancer feel better emotionally.
What could go wrong
This is a small, early-stage study with only 100 participants. The workshop may not lead to lasting improvements in mental wellness, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with a hematologic malignancy diagnosis in treatment or after treatment is completed, who is currently between the ages of 18 and 39 (young adult), or the informal caregiver of a young adult blood cancer patient * Located within the U.S., Canada, or U.S. territories * Able to read and write in English Exclusion Criteria: * Located outside of the U.S., Canada, or its territories * Participant is a minor aged 17 years or below

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematologic malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematologic malignancy

Contacts and locations

Locations

  • Blood Cancer United

    Washington D.C., District of Columbia, 20005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.